Regeneron Pharmaceuticals Inc (REGN) Receives Consensus Rating of “Hold” from Brokerages

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have been given an average recommendation of “Hold” by the thirty ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $461.51.

REGN has been the subject of a number of recent research reports. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $450.00 to $395.00 in a research note on Friday, October 20th. Guggenheim reaffirmed a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, October 23rd. Finally, Robert W. Baird raised Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research report on Friday, November 3rd.

In related news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.80% of the company’s stock.

Several institutional investors have recently bought and sold shares of REGN. Harding Loevner LP boosted its stake in Regeneron Pharmaceuticals by 589.2% during the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares during the last quarter. Polen Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock valued at $522,413,000 after purchasing an additional 15,931 shares during the last quarter. American Century Companies Inc. boosted its stake in Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock valued at $410,257,000 after purchasing an additional 20,218 shares during the last quarter. Geode Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 880,481 shares of the biopharmaceutical company’s stock valued at $330,385,000 after purchasing an additional 30,581 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Regeneron Pharmaceuticals by 516.8% during the 4th quarter. Renaissance Technologies LLC now owns 579,562 shares of the biopharmaceutical company’s stock valued at $217,892,000 after purchasing an additional 485,600 shares during the last quarter. Institutional investors own 65.89% of the company’s stock.

Regeneron Pharmaceuticals (REGN) traded down $18.10 during midday trading on Tuesday, hitting $324.57. The stock had a trading volume of 1,557,083 shares, compared to its average volume of 1,066,957. Regeneron Pharmaceuticals has a 12 month low of $314.99 and a 12 month high of $543.55. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82. The company has a market cap of $34,890.00, a price-to-earnings ratio of 31.45, a PEG ratio of 1.27 and a beta of 1.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same quarter in the previous year, the company posted $3.04 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 28.9% on a year-over-year basis. sell-side analysts anticipate that Regeneron Pharmaceuticals will post 14.13 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/02/13/regeneron-pharmaceuticals-inc-regn-receives-consensus-rating-of-hold-from-brokerages.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply